Kura Oncology (KURA) Operating Expenses (2013 - 2026)

Kura Oncology (KURA) has 14 years of Operating Expenses data on file, last reported at $97.1 million in Q1 2026.

• Quarterly Operating Expenses rose 23.19% year-over-year to $97.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $97.1 million (down 64.23% YoY) and the FY2025 annual result came in at $371.1 million, up 50.2% from the prior year.
• Operating Expenses rose to $97.1 million in Q1 2026 per KURA's latest filing, from $78.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $97.1 million in Q1 2026 and bottomed at $32.8 million in Q1 2022.
• The 5-year median for Operating Expenses is $44.6 million (2023), against an average of $52.0 million.
• The widest annual swing landed in 2022, when Operating Expenses grew 5.01%; it then surged 63.25% in 2024.
• Tracing KURA's Operating Expenses over 5 years: stood at $35.2 million in 2022, then soared by 33.01% to $46.8 million in 2023, then jumped by 63.25% to $76.3 million in 2024, then climbed by 3.24% to $78.8 million in 2025, then gained by 23.19% to $97.1 million in 2026.
• Per Business Quant, the three latest KURA Operating Expenses figures stand at $97.1 million (Q1 2026), $78.8 million (Q1 2025), and $76.3 million (Q4 2024).

Peer Comparison